The agent everolimus showed real promise in treating patients with nonfunctional neuroendocrine tumors of lung or gastrointestinal origin, a new study reveals.
Methylnaltrexone, a drug approved to treat opioid-induced constipation showed promise when administered to advanced cancer patients, a new study reveals.
Patients with stage III melanoma with a high risk of recurrence after surgery can now be treated with Yervoy as the FDA has expanded the use of this melanoma drug.
Pancreatic cancer patients who undergo complex tumor removal operations survive longer, according to a Mayo Clinic gastrointestinal surgeon.
A viral immunotherapy got approved by EU regulators for the treatment of melanoma patients.
U.S regulators approved trabectedin (Yondelis) for the treatment of certain types of unresectable or metastatic soft-tissue sarcomas.
Lenvatinib (Lenvima) benefited metastatic differentiated thyroid cancer patients across all common sites of metastasis, scientists reported.
Breast conservation therapy should be suggested as a treatment option to breast cancer patients with larger tumors, researchers reported.
Data from a phase 3 trial and various sub-analyses show that lenvatinib improved progression-free survival in patients with differentiated thyroid cancer.
The combination of irinotecan liposome injection with fluorouracil and leucovorin has been approved by the FDA for the treatment of metastatic pancreatic cancer.
Advance practice nurses can offer high-quality, cost-effective care in high-risk patients who receive chemo-radiation therapy for head and neck cancer, a new research shows.
Cervical cancer patients had less bowel side effects when treated with image-guided intensity-modulated radiation therapy, a new study reveals.
Radiation therapy that targets only the involved lymph nodes regions results in less toxicity without affecting overall survival rates in esophageal cancer patients.
A subset of patients with metastatic melanoma benefited from a combined treatment of immunotherapy and palliative radiation therapy, a new research reveals.
A shorter radiation therapy schedule was equally beneficial as a longer treatment schedule for some men with low-risk prostate cancer.
Cancer patients with painful bone metastases experienced fewer and less severe radiation-induced pain flare episodes with the steroid dexamethasone.
Non-small cell lung cancer patients who received intensity modulated radiation therapy had lower occurrence of severe pneumonitis, a secondary analysis reported.
A new test can detect for which testicular cancer patients surveillance would be the best choice, sparing them from the side-effects of chemotherapy.
The analysis of a trial revealed that HER2-positive breast cancer patients benefited more from receiving chemotherapy alone than chemotherapy plus trastuzumab.
Patients with lung cancer patients survived longer if their management included a follow-up program based on computer tomography (CT) of the chest, a new study shows.
U.S. regulators approved nivolumab for the treatment of patients with non-squamous non-small cell lung cancer.
A new study sheds light on the dietary habits of cancer survivors pointing out the need for dietary interventions in order to prevent a variety of health problems.
Surgical removal of metastatic melanoma helped patients live more than twice as long as those who receive only medical therapy, according to the results of a new study.
The breakthrough immunotherapy Keytruda got approved by the U.S. FDA to treat patients with advanced non-small cell lung cancer.
Breast cancer survivors improved their physical functionality lost due to chemotherapy when participated at a six-month weight training program, a new study shows.
U.S. regulators approved the combination of the immunotherapies nivolumab and ipilimumab for the treatment of patients with melanoma without a BRAF mutation.
Patients of advanced BRAF-mutant melanoma survived longer when treated with a combination of the targeted therapies dabrafenib and trametinib.
New drug Afinitor® (everolimus) reduced the disease progression risk in patients with advanced, nonfunctional neuroendocrine tumors of gastrointestinal or lung origin.
Children born to mothers affected by cancer had no significant differences in mental development compared to children from the general population.
Roche’s new immune-system boosting drug, atezolizumab, improved patient outcomes for lung and bladder cancer patients, according to separate phase 2 trials.